Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.61 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.61 |
| ▸ | CYP4Z1 | Q86W10 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.44 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676514 | 0.86 | CYP4F2 (0.59) | CYP4F2CYP4A11CYP4Z1JAK2JAK1 | |
| SCHEMBL4734773 | 0.85 | TSHR (0.51) | CYP4F2CYP4A11CYP4Z1TSHRSMN1; SMN2 | |
| SCHEMBL30605730 | 0.84 | CYP4F2 (0.58) | CYP4F2CYP4A11CYP4Z1JAK2JAK1 | |
| SCHEMBL8663044 | 0.84 | CYP4F2 (0.58) | CYP4F2CYP4A11CYP4Z1JAK2JAK1 | |
| SCHEMBL4590909 | 0.84 | CYP4F2 (0.58) | CYP4F2CYP4A11CYP4Z1JAK2JAK1 | |
| SCHEMBL4903126 | 0.84 | CYP4F2 (0.58) | CYP4F2CYP4A11CYP4Z1SMN1; SMN2JAK2 | |
| SCHEMBL29089598 | 0.84 | CYP4F2 (0.58) | CYP4F2CYP4A11CYP4Z1JAK2JAK1 | |
| SCHEMBL10663309 | 0.84 | TSHR (0.45) | CYP4F2CYP4A11CYP4Z1TSHRSMN1; SMN2 | |
| SCHEMBL2503936 | 0.83 | CYP4Z1 (0.50) | CYP4F2CYP4A11CYP4Z1TSHRSMN1; SMN2 | |
| SCHEMBL6307266 | 0.83 | CYP4F2 (0.56) | CYP4F2CYP4A11CYP4Z1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0070185-B1 | PREPARATION OF LOWER ALKYL 2-FORMYL-3-(6-METHYL-3-PYRIDINYL)-PROPIONATES | SMITHKLINE BECKMAN CORPORATION (US) | 1985-04-10 | — | — | EP | claimed |
| US-8173820-B2 | Compounds which potentiate the AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-20110021578-A1 | Compounds which Potentiate the AMPA Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| EP-2222632-A1 | COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | Glaxo Group Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009080637-A1 | COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
| US-7196080-B2 | Respiratory system disordeers; chronic obstructive pulminary disease | ASTELLAS PHARMA INC. (JP) | 2007-03-27 | — | — | US | disclosed |
| US-5763461-A | ANTIPICORNAVIRAL AGENTS | SANOFI (FR) | 1998-06-09 | — | — | US | disclosed |
| US-5618821-A | VIRICIDES, PICORNAVIRUS | SANOFI, S.A. (FR) | 1997-04-08 | — | — | US | disclosed |
| WO-1995031438-A1 | THERAPEUTIC PHENOXYALKYLHETEROCYCLES | SANOFI WINTHROP, INC. (US) | 1995-11-23 | — | — | WO | disclosed |
| EP-0206294-B1 | ALKYL ESTERS OF 3-HYDROXY-3-(2-METHYL-5-PYRIDYL)-PROPIONIC ACID | LONZA AG (CH) | 1990-05-16 | — | — | EP | disclosed |
| EP-0017680-A1 | Pyrimidone derivatives, process for preparing them and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-10-29 | — | — | EP | disclosed |
| US-4227000-A | Intermediates in the process for making histamine antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-10-07 | — | — | US | disclosed |
| EP-0015138-A1 | Pyrimidone derivatives, processes for their preparation and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-09-03 | — | — | EP | disclosed |
| US-4216318-A | HISTAMINE HZ-ANTAGONISTS, ISOCYTOSINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-08-05 | — | — | US | disclosed |
| EP-0013071-A1 | Pyrimidinone derivatives, processes for preparing them and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-07-09 | — | — | EP | disclosed |
| WO-1980000966-A1 | NEW HISTAMINE H2-ANTAGONISTS | SMITH KLINE FRENCH LAB (GB) | 1980-05-15 | — | — | WO | disclosed |
| EP-0007232-A1 | Iso(thio)ureas, processes for their preparation and compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-01-23 | — | — | EP | disclosed |
| EP-0004793-A2 | 2-nitro aminopyrimidone derivatives, a process for their preparation and their use to prepare 2-aminopyrimidone derivatives which have histamine H2-antagonist activity | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-10-17 | — | — | EP | disclosed |
| EP-0003677-A2 | Pyrimidones, processes for their preparation and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-08-22 | — | — | EP | disclosed |
| US-4154834-A | HETEROCYCLIC-(THIO)ALKYLAMINO SUBSTITUTED-4-PYRIMIDONE OR -THIONES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021578-A1 | Compounds which Potentiate the AMPA Receptor and Uses Thereof in Medicine | GRIN1, GRM1, GRM2 | CYP4F2 662/4885CYP4A11 640/4885CYP4Z1 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.